Vitamin D3 for Life

Live Enlightened

Research libraryVitamin D3 For Life
Study design and methods

Primary relevance to vitamin D Vitamin D is a stated subject of this paper.

Vitamin D is a stated subject of this paper; the supporting source evidence is shown below.

Why this paper is included

Supporting source evidence:

This retrospective study evaluated whether patients with path-VF receive appropriate vitamin D3 (Vit.D3) supplementation and assessed the dose: response relationship between daily intake and path-VF risk, particularly in older adults.

Source: Abstract. View original paper

Relevance classification does not establish study quality, causation or editorial approval.

Study design Case-control study.

Case-control study

Compares people with an outcome against people without it, examining exposures.

Meta-analysis unclear · Blinding unclear / not reported · Human research reported

How this paper was classified

Automatic source-based classification; awaiting editorial verification. This is not a quality score.

In this retrospective case: control study, we evaluated 210 patients who underwent spinal surgical treatments, including balloon kyphoplasty and PISF, in the thoracic and lumbar regions at a single spine centre between 2022 and 2023.

Source: Methods.

Patients were classified into two cohorts: the path-VF group, comprising individuals diagnosed with path-VF, and the control group, comprising patients without evidence of path-VF.

Source: Methods.

View supporting evidence in the original paper

What the study types mean
Systematic review
Uses explicit methods to identify, assess and summarise research on a defined question.
Scoping review
Maps the extent and characteristics of research on a topic.
Narrative review
Discusses existing research; systematic-review methods have not been established by this classification.
Review / evidence synthesis
Reviews existing research; the exact review methods need further assessment.
Randomised controlled trial
Assigns participants or groups to comparison interventions by chance.
Non-randomised intervention study
Examines an intervention without random allocation.
Cohort study
Examines exposures and outcomes over time within a defined group.
Case-control study
Compares people with an outcome against people without it, examining exposures.
Cross-sectional study
Examines a population at a particular point in time.
Observational study
Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
Case report
Describes an individual case.
Case series
Describes a group of individual cases.
Secondary analysis
Analyses existing study data; this paper is not automatically another independent trial.
Laboratory study
Investigates biological processes in a laboratory setting.
Qualitative study
Examines experiences or meanings using qualitative methods.
Genetic instrumental-variable study
Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
Study protocol
Describes planned methods and is not evidence that the planned study has reported results.
Multiple reported designs
More than one design is explicitly reported; examine the supporting methods.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.

Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.

Full studies

Low-Dose Vitamin D3 Supplementation: Associations with Vertebral Fragility and Pedicle Screw Loosening

Case-control study · Journal of Clinical Medicine · 2025

Original publication title

Low-Dose Vitamin D3 Supplementation: Associations with Vertebral Fragility and Pedicle Screw Loosening

Jun Li; André Strahl; Beate Kunze; Stefan Krebs; Martin Stangenberg; Lennart Viezens; Patrick Strube; Marc Dreimann

© 2025 by the authors.

Original publication · Publisher record · CC BY 4.0

Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.

Authors’ conclusion

This study found a clear dose: response relationship between daily Vit.D3 intake and path-VF risk. Patients with path-VF received significantly lower Vit.D3 doses than controls. The elevated risk observed in the Low-Dose group, particularly in those over 67.5 years, suggests that commonly recommended minimum doses may not provide sufficient protection. A threshold of approximately 1900 IU/day may be relevant for risk reduction in elderly patients.

These effects are unlikely to result solely from improvements in BMD but may instead reflect broader physiological benefits of adequate Vit.D3 availability, including contributions to muscle strength, metabolic balance, and reduced inflammation. Overall, these findings highlight the potential value of tailored Vit.D3 supplementation strategies in spinal surgery patients at elevated risk of vertebral fragility. Further prospective studies with larger cohorts and systematic monitoring of serum 25(OH)D levels are needed to define and validate clinically relevant dosing thresholds.

An extract from the source publication. Read it in context.

At a glance

Study background

What background does the paper provide?

Vitamin D (Vit.D) deficiency is a well-recognised risk factor for impaired spinal health and is closely associated with pathological vertebral fragility (path-VF). It increases the risk of fragility fractures (FF) [1], delays postoperative recovery and physical rehabilitation [2], reduces spinal fusion success rates [3], and contributes to implant-related complications such as early pedicle screw loosening (PSL). Despite its clinical relevance, the risks of path-VF are often insufficiently assessed in clinical practice prior to posterior instrumented spinal fusion (PISF).

Only 44% of spine surgeons perform preoperative bone mineral density (BMD) evaluations, and just 12% assess metabolic laboratory parameters, including 25-hydroxyvitamin-D (25(OH)D), parathyroid hormone, and calcium levels [4].

Although the above considerations support the role of Vit.D, perioperative supplementation in bone surgeries, especially in spine surgery, has shown inconsistent results. Some study reported improved fusion rates, symptom relief, and recovery despite small sample sizes [3]. Others, show no clear postoperative benefits and no consistent dose: response relationship [5,6]. Similar inconsistencies are seen in broader orthopedic research, often limited by heterogeneous designs and low methodological quality [7,8].

The biomechanical integrity of the vertebrae is maintained through dynamic bone remodelling, adapting to internal and external influences such as ageing, nutrition, biomechanical stress, menopause, chronic inflammatory conditions, and other systemic disorders [9,10]. Disruption of this osteogenic: osteoclastic balance significantly reduces BMD, predisposing vertebrae to fragility and increasing the risk of path-VF [11]. Vit.D is crucial for bone development and mechanical strength, facilitating calcium and phosphate metabolism [12,13]. Among available Vit.D supplements, vitamin D3 (Vit.D3) demonstrates superior efficacy in elevating serum 25(OH)D concentrations compared with vitamin D2 (Vit.D2) [14].

Existing international guidelines for Vit.D3 supplementation in adults vary widely in both age grouping and dosage and often provide ambiguous recommendations regarding target populations (typically limited to categories such as infants, children, adults, and pregnant or lactating women), initiation timing, and optimal dosage. Some countries make no age distinction for adults, while others introduce multiple age categories but recommend almost identical adequate intake levels [15,16,17,18,19]. Internationally [15,16,17,18,19], daily doses range from as low as 9 μg (360 IU) to as high as 100 μg (4000 IU).

This discrepancy fosters subjective decision-making in clinical practice, frequently overlooking certain patient groups (particularly males) and leading to arbitrary dosing within this broad range.

This study was performed to evaluate Vit.D3 supplementation in spinal surgery patients and to determine whether those at risk of path-VF (including FF and early PSL following PISF) receive appropriate supplementation compared with those without such risk. In addition, this study sought to identify specific cut-off values for age and daily Vit.D3 dosage that may guide supplementation strategies. The findings may provide evidence to refine clinical guidelines for Vit.D3 supplementation, with the aim of reducing the incidence of path-VF and its associated complications in spinal surgery patients.

Source: 1. Introduction Source: 1. Introduction Source: 1. Introduction Source: 1. Introduction Source: 1. Introduction

Study methods

What methods does the paper describe?

2.1. Patients

In this retrospective case: control study, we evaluated 210 patients who underwent spinal surgical treatments, including balloon kyphoplasty and PISF, in the thoracic and lumbar regions at a single spine centre between 2022 and 2023.

2.2. Definitions of Path-VF and Early PSL

For this study, the diagnostic criteria for path-VF were based on the framework established in a previous study [20], with adaptations to the present research context. A diagnosis of path-VF was considered if any of the following conditions were met, after histological exclusion of tumour-related fractures:

  • (1)

    cases requiring balloon kyphoplasty for path-VF,

  • (2)

    intraoperative use of cement-augmented pedicle screws during the first PISF, or

  • (3)

    occurrence of non-traumatic PSL within 6 months after the initial PISF in the absence of prior screw reinforcement.

The indications for PISF in this study included severe degenerative lumbar stenosis with instability, idiopathic scoliosis, advanced spondylolisthesis, and de novo lumbar scoliosis. Patients with spondylodiscitis or spinal tumours were excluded.

Among the available techniques for enhancing screw fixation in osteoporotic vertebrae, cement augmentation is regarded as the most widely used and effective [21,22]. Therefore, only cement-augmented screws were used in the present cohort, while other reinforcement options (e.g., expandable screws, specialised thread designs, or bioactive-coated implants) were excluded.

The decision to perform screw reinforcement was made by senior spine surgeons following thorough preoperative assessment. Consistent with earlier findings, early PSL (<6 months) is predominantly associated with low BMD and reduced bone quality [23], whereas later PSL (>1 year) is more often related to mechanical overload, adjacent segment degeneration, suboptimal implant positioning, or chronic low-grade infection [24,25,26]. Based on these considerations, a 6-month threshold was applied in this study to define early PSL.

PSL was diagnosed using computed tomography (CT) imaging based on either a radiolucent rim > 1 mm around the screw or signs of screw pull-out/cut-out [26]. To reduce radiation exposure and costs, CT was limited to patients with severe symptoms such as intense localised pain or significant activity restriction [27].

2.3. Grouping

Patients were classified into two cohorts: the path-VF group, comprising individuals diagnosed with path-VF, and the control group, comprising patients without evidence of path-VF. Preoperative demographic data, including age, sex, and daily Vit.D3 supplementation dosage, were recorded for all participants.

2.4. Categorisation of Vit.D3 Dosage

Data on vitamin D supplementation were retrieved from general practitioner medication records or, when unavailable, collected during preoperative patient interviews.

To assess the impact of daily Vit.D3 intake, patients were categorised into three dosage groups: Zero-Dose (0 IU/day), Low-Dose (<2000 IU/day), and High-Dose (≥2000 IU/day). Patients whose Vit.D3 supplementation dosage changed between the PISF and the 6-month follow-up were excluded from the analysis.

Based on our previous study [20], which identified 67.5 years as the optimal age threshold for predicting path-VF risk, analyses were performed for the overall cohort and further stratified into subgroups above and below this threshold to examine the relationship between Vit.D3 intake and path-VF risk.

2.5. Measurement of Vertebral Hounsfield Units (HU)

To validate the definition of path-VF used in this study and to confirm the robustness of the subsequent grouping, vertebral bone quality was assessed using preoperative CT-based HU measurements. Among the 210 patients, only 8 had dual-energy X-ray absorptiometry (DEXA) results available before surgery. Preoperative lumbar spine CT scans were retrospectively evaluated in 88 patients. HU values were measured from Th11 to L5 using elliptical region of interest placed in the cancellous bone between the upper and middle thirds of each vertebral body, excluding cortical areas.

Regions containing vascular structures, Schmorl’s nodes, sclerosis, or tumorous changes were excluded. For each patient, the mean HU value from Th11 to L5 was calculated and used in subsequent analyses.

2.6. Statistical Analysis

All statistical analyses were conducted using R software version 4.4.1, 14 June 2024 (The R Foundation for Statistical Computing, Vienna, Austria). Continuous variables are reported as mean ± standard deviation, and statistical significance was defined as a two-tailed p-value of <0.05.

To compare means of numeric variables, the data normality was assessed previously using the Shapiro: Wilk test and Kolmogorov: Smirnov test, and variance homogeneity was verified using Levene’s test and the F-test. Due to non-normality, variance inhomogeneity, or limited sample size, group comparisons for age, daily Vit.D3 dosage, and HU values were performed using the Mann: Whitney U test. Effect sizes were reported as rank-biserial correlation coefficients (r), with r > 0.3 and r > 0.5 interpreted as medium and large effects, respectively.

Associations between Vit.D3 dosage categories and the risk of path-VF or path-VF with early PSL were examined using Fisher’s exact test, yielding odds ratios (ORs) with corresponding 95% confidence intervals (CIs).

To further explore potential predictors, multiple logistic regression was performed, incorporating sex, age, and Vit.D3 dosage categories (Zero-, Low-, and High-Dose) as independent variables. Multicollinearity among predictors was evaluated using variance inflation factors (VIF). A VIF < 5 was considered acceptable. Receiver operating characteristic (ROC) curve analysis was used to identify potential dosage thresholds, with an area under the curve (AUC) of ≥0.8 interpreted as indicating excellent discriminative ability.

Source: 2. Materials and Methods Source: 2. Materials and Methods Source: 2. Materials and Methods Source: 2. Materials and Methods Source: 2. Materials and Methods Source: 2. Materials and Methods

Results: Demographics of the Study Cohort

The study cohort comprised 210 patients with a mean age of 67.5 years (range 18.5 to 87.9 years), including 80 males and 130 females. Of these, 84 patients were classified into the path-VF group and 126 into the control group. Osteoporosis was pre-diagnosed in 42 patients using DEXA or quantitative CT, of whom 13 did not take Vit.D3, 20 received a low dose, and 9 received a high dose. In total, 53 patients in the cohort received Vit.D3 supplementation at varying doses.

Detailed demographic characteristics are summarised in Table 1.

Table 1

Demographics of the involved patients.

Age (Years)
n Min.MeanMax.SD
Total21018.567.587.915.4
  Male8018.563.987.617.9
  Female13023.169.787.913.1
Path-VF group8453.075.387.99.0
  Male2253.074.087.010.6
  Female6252.075.887.08.5
Control group12618.562.287.616.5
  Male5818.560.087.018.7
  Female6823.064.186.014.2
Zero Vit.D3-Suplement (0 IU/Day)15718.565.187.416.1
Low Vit.D3-Suplement (<2000 IU/Day)3353.075.487.79.2
High Vit.D3-Suplement (≥2000 IU/Day)2052.473.187.911.2
Diagnosed Osteoporosis4253.076.287.98.2
  Osteoporosis with zero Vit.D3-Suplement1363.073.585.26.8
  Osteoporosis with low Vit.D3-Suplement2053.077.786.89.1
  Osteoporosis with high Vit.D3-Suplement968.579.087.97.9
Patients with Hounsfield units Value8831.969.387.712.7

Path-VF: pathological vertebral fragility, SD: Standard deviation.

Source: 3.1. Demographics of the Study Cohort Source: 3.1. Demographics of the Study Cohort

Results: HU Values in the Path-VF and Control Groups

As expected, HU measurements confirmed the validity of the applied path-VF definition and the derived grouping. The path-VF group showed significantly lower mean vertebral HU values than did the control group (71.9 ± 29.1 vs. 133.5 ± 52.6, p < 0.001, r = 0.61), consistent with reduced bone quality in patients meeting the path-VF criteria.

Source: 3.2. HU Values in the Path-VF and Control Groups

Differences in Daily Doses of Vit.D3 Between the Path-VF and Control Groups

Results: Differences in Daily Doses of Vit.D3 Between the Path-VF and Control Groups

Oral daily Vit.D3 supplementation doses were compared between the path-VF and control groups using the Mann: Whitney U test. Patients in the path-VF group received significantly lower daily doses than those in the control group (Table 2).

Figure 1 illustrates the age distribution of Vit.D3 supplementation. Patients without Vit.D3 supplementation and without path-VF risk were spread across all age ranges. By contrast, those not receiving Vit.D3 but meeting the path-VF criteria for FF or early PSL were mainly observed from approximately 50 years of age onwards. The previously established age threshold for path-VF risk (67.5 years) [20] is indicated by a vertical dashed line. Among patients receiving Vit.D3, daily doses below 2000 IU were predominantly found in the path-VF group, particularly in individuals above the 67.5-year threshold.

By comparison, only 6 of 33 patients in the control group fell into this low-dose category. Conversely, most patients receiving ≥ 2000 IU/day (12 of 20) were in the control group and showed no path-VF risk.

Table 2

Vit.D3 Doses in At-risk and Without-risk groups.

n MeanSD p r
Path-VF group351431.41055.7<0.001 ***0.36
Control group182366.71186.7

SD: standard deviation, *** p < 0.001.

Source: 3.3. Differences in Daily Doses of Vit.D3 Between the Path-VF and Control Groups Source: 3.3. Differences in Daily Doses of Vit.D3 Between the Path-VF and Control Groups Source: 3.3. Differences in Daily Doses of Vit.D3 Between the Path-VF and Control Groups

Results: ORs of Oral Vit.D3 Dosages for Path-VF Risk

ORs for different oral Vit.D3 dosage categories and path-VF risk were calculated for the overall cohort (n = 210) and for the subgroup of patients aged >67.5 years (Figure 2), with diagnosed osteoporosis serving as a positive control.

As expected, osteoporosis was significantly associated with increased path-VF risk in both the overall cohort (OR: 14.8, 95% CI [5.7 to 45.7], p < 0.001) and the older subgroup (OR: 6.4, 95% CI [2.3 to 20.9], p < 0.001). The Vit.D3 dosage showed similar patterns in both analyses. Compared with patients taking Low-Dose Vit.D3, those in the Zero-Dose category had a significantly lower path-VF risk in the overall cohort (OR: 0.10, 95% CI [0.03 to 0.27], p < 0.001) and in the older subgroup (OR: 0.11, 95% CI [0.02 to 0.43], p < 0.001).

This apparent lower risk in the Zero-Dose group than in the Low-Dose group will be further considered in the Discussion. Low-Dose supplementation was associated with a significantly higher path-VF risk than was High-Dose supplementation (overall OR: 6.5, 95% CI [1.6 to 28.9], p = 0.003; older subgroup OR: 8.6, 95% CI [1.6 to 64.2], p = 0.008). Zero-Dose versus High-Dose showed no significant association with path-VF (OR not different from 1; both p-values > 0.05).

Multiple logistic regression analysis assessed the associations between path-VF occurrence and age, sex, and daily Vit.D3 dosage (Zero-, Low-, and High-Dose). All predictors showed VIF values close to 1 (range: 1.00 to 1.07), indicating no evidence of multicollinearity. As shown in Table 3, female sex was positively but not significantly associated with path-VF risk (β = 0.64, p > 0.05). Higher daily Vit.D3 dosage was linked to a small yet statistically significant reduction in path-VF occurrence (β = −0.001, p = 0.018).

Increasing age was significantly associated with elevated path-VF risk (β = 0.08, p = 0.031). ROC analysis for daily Vit.D3 dosage identified a threshold of 1900 IU/day, yielding an AUC of 0.805 (Figure 3), indicating good predictive accuracy.

Table 3

Multiple logistic regression.

β SE β z p
(Intercept)−4.342.94−1.480.139
Gender0.640.920.690.490
Vit.D3 Dose−0.0010.0004−2.370.018*
Age0.080.042.150.031*

SE: standard error, * p < 0.05.

Source: 3.4. ORs of Oral Vit.D3 Dosages for Path-VF Risk Source: 3.4. ORs of Oral Vit.D3 Dosages for Path-VF Risk Source: 3.4. ORs of Oral Vit.D3 Dosages for Path-VF Risk Source: 3.4. ORs of Oral Vit.D3 Dosages for Path-VF Risk

Global Variability and Clinical Uncertainty

Discussion: Global Variability and Clinical Uncertainty

International guidelines for Vit.D3 supplementation differ substantially in both dosage and age-group definitions. Some make no age distinctions, while others define multiple age brackets but recommend nearly identical adequate intake levels. Across all guidelines, the gap between the adequate intake and the upper level of intake (4000 IU/day) remains large. This complicates clinical decisions, particularly for spinal surgeons managing patients at risk of path-VF. For example, the United States recommends 600 IU/day for adults aged 19 to 70 years and 800 IU/day for those aged ≥71 years [15].

The European Food Safety Authority advises 600 IU/day for all adults and sets an upper level of intake of 4000 IU/day, while the German osteoporosis S3 guideline recommends 800 IU/day, advising against exceeding 2000 to 4000 IU/day [16,17]. The UK sets a range of 400 to 4000 IU/day for all adults without age subdivision [18]. South Korea recommends 400 IU/day for adults aged 19 to 49 years and 600 IU/day for those aged ≥50 years, with an upper limit of 4000 IU/day [19].

Japan recommends 360 to 4000 IU/day for all adults, subdivided into multiple age categories [39]. Such variability fosters subjective prescribing practices and underscores the lack of evidence-based dosing thresholds, a concern that is particularly relevant for spinal surgery patients.

Source: 4.2. Global Variability and Clinical Uncertainty

Study limitations

What limitations does the paper describe?

This study has several limitations. First, its retrospective design limits the ability to establish causality between Vit.D3 dosage and path-VF occurrence. Second, serum 25(OH)D levels were not routinely assessed, preventing correlation analyses between measured Vit.D status and clinical outcomes. Third, the sample size in the High-Dose group was relatively small, which may have reduced the statistical power to detect significant associations.

Finally, other confounding factors, such as comorbidities, nutritional status, or physical activity levels, were not systematically controlled and may have influenced the observed relationships. In particular, the absence of objective health-status indicators introduces a potential ‘healthy user’ bias in the Zero-Dose group, meaning that their apparently lower risk may partly reflect better baseline physiological reserve rather than a true protective effect of no supplementation.

Source: 5. Limitations Source: 5. Limitations

Results

3.1. Demographics of the Study Cohort

The study cohort comprised 210 patients with a mean age of 67.5 years (range 18.5 to 87.9 years), including 80 males and 130 females. Of these, 84 patients were classified into the path-VF group and 126 into the control group. Osteoporosis was pre-diagnosed in 42 patients using DEXA or quantitative CT, of whom 13 did not take Vit.D3, 20 received a low dose, and 9 received a high dose. In total, 53 patients in the cohort received Vit.D3 supplementation at varying doses.

Detailed demographic characteristics are summarised in Table 1.

3.2. HU Values in the Path-VF and Control Groups

As expected, HU measurements confirmed the validity of the applied path-VF definition and the derived grouping. The path-VF group showed significantly lower mean vertebral HU values than did the control group (71.9 ± 29.1 vs. 133.5 ± 52.6, p < 0.001, r = 0.61), consistent with reduced bone quality in patients meeting the path-VF criteria.

3.3. Differences in Daily Doses of Vit.D3 Between the Path-VF and Control Groups

Oral daily Vit.D3 supplementation doses were compared between the path-VF and control groups using the Mann: Whitney U test. Patients in the path-VF group received significantly lower daily doses than those in the control group (Table 2).

Figure 1 illustrates the age distribution of Vit.D3 supplementation. Patients without Vit.D3 supplementation and without path-VF risk were spread across all age ranges. By contrast, those not receiving Vit.D3 but meeting the path-VF criteria for FF or early PSL were mainly observed from approximately 50 years of age onwards. The previously established age threshold for path-VF risk (67.5 years) [20] is indicated by a vertical dashed line. Among patients receiving Vit.D3, daily doses below 2000 IU were predominantly found in the path-VF group, particularly in individuals above the 67.5-year threshold.

By comparison, only 6 of 33 patients in the control group fell into this low-dose category. Conversely, most patients receiving ≥ 2000 IU/day (12 of 20) were in the control group and showed no path-VF risk.

3.4. ORs of Oral Vit.D3 Dosages for Path-VF Risk

ORs for different oral Vit.D3 dosage categories and path-VF risk were calculated for the overall cohort (n = 210) and for the subgroup of patients aged >67.5 years (Figure 2), with diagnosed osteoporosis serving as a positive control.

As expected, osteoporosis was significantly associated with increased path-VF risk in both the overall cohort (OR: 14.8, 95% CI [5.7 to 45.7], p < 0.001) and the older subgroup (OR: 6.4, 95% CI [2.3 to 20.9], p < 0.001). The Vit.D3 dosage showed similar patterns in both analyses. Compared with patients taking Low-Dose Vit.D3, those in the Zero-Dose category had a significantly lower path-VF risk in the overall cohort (OR: 0.10, 95% CI [0.03 to 0.27], p < 0.001) and in the older subgroup (OR: 0.11, 95% CI [0.02 to 0.43], p < 0.001).

This apparent lower risk in the Zero-Dose group than in the Low-Dose group will be further considered in the Discussion. Low-Dose supplementation was associated with a significantly higher path-VF risk than was High-Dose supplementation (overall OR: 6.5, 95% CI [1.6 to 28.9], p = 0.003; older subgroup OR: 8.6, 95% CI [1.6 to 64.2], p = 0.008). Zero-Dose versus High-Dose showed no significant association with path-VF (OR not different from 1; both p-values > 0.05).

Multiple logistic regression analysis assessed the associations between path-VF occurrence and age, sex, and daily Vit.D3 dosage (Zero-, Low-, and High-Dose). All predictors showed VIF values close to 1 (range: 1.00 to 1.07), indicating no evidence of multicollinearity. As shown in Table 3, female sex was positively but not significantly associated with path-VF risk (β = 0.64, p > 0.05). Higher daily Vit.D3 dosage was linked to a small yet statistically significant reduction in path-VF occurrence (β = −0.001, p = 0.018).

Increasing age was significantly associated with elevated path-VF risk (β = 0.08, p = 0.031). ROC analysis for daily Vit.D3 dosage identified a threshold of 1900 IU/day, yielding an AUC of 0.805 (Figure 3), indicating good predictive accuracy.

3.5. Effects of Different Vit.D3 Daily Doses on HU Values

Firstly, HU values in the path-VF group were significantly lower than in the control group (p < 0.001) (Figure 4A). The violin plots show that HU values for path-VF patients were concentrated below 100, whereas control patients displayed a broader distribution towards higher values. By contrast, patient age showed the opposite pattern (Figure 4B), with those in the path-VF group being older (74.6 ± 9.1 years) than those in the control group (63.7 ± 13.7 years, p < 0.001, r = 0.42).

We next examined the relationship between Vit.D3 dosage, HU values, and age. Mean HU values (Figure 5A) were 86.3 ± 37.9 (High-Dose, n = 11), 71.4 ± 27.4 (Low-Dose, n = 16), and 112.9 ± 55.7 (Zero-Dose, n = 61), with a statistically significant difference observed only between the Low-Dose and Zero-Dose groups (p = 0.004, r = 0.55). Corresponding mean ages (Figure 5B) were 70.3 ± 10.9, 76.9 ± 9.2, and 67.1 ± 13.2 years, respectively, with a significant difference again between the Low-Dose and Zero-Dose groups (p = 0.006, r = 0.53).

All comparisons involving the High-Dose group showed no statistically significant differences, with small effect sizes (r < 0.3), suggesting that the limited sample size may have contributed to the lack of significance.

Table 1

Demographics of the involved patients.

Age (Years)
n Min.MeanMax.SD
Total21018.567.587.915.4
  Male8018.563.987.617.9
  Female13023.169.787.913.1
Path-VF group8453.075.387.99.0
  Male2253.074.087.010.6
  Female6252.075.887.08.5
Control group12618.562.287.616.5
  Male5818.560.087.018.7
  Female6823.064.186.014.2
Zero Vit.D3-Suplement (0 IU/Day)15718.565.187.416.1
Low Vit.D3-Suplement (<2000 IU/Day)3353.075.487.79.2
High Vit.D3-Suplement (≥2000 IU/Day)2052.473.187.911.2
Diagnosed Osteoporosis4253.076.287.98.2
  Osteoporosis with zero Vit.D3-Suplement1363.073.585.26.8
  Osteoporosis with low Vit.D3-Suplement2053.077.786.89.1
  Osteoporosis with high Vit.D3-Suplement968.579.087.97.9
Patients with Hounsfield units Value8831.969.387.712.7

Path-VF: pathological vertebral fragility, SD: Standard deviation.

Table 2

Vit.D3 Doses in At-risk and Without-risk groups.

n MeanSD p r
Path-VF group351431.41055.7<0.001 ***0.36
Control group182366.71186.7

SD: standard deviation, *** p < 0.001.

Table 3

Multiple logistic regression.

β SE β z p
(Intercept)−4.342.94−1.480.139
Gender0.640.920.690.490
Vit.D3 Dose−0.0010.0004−2.370.018*
Age0.080.042.150.031*

SE: standard error, * p < 0.05.

Source: 3. Results Source: 3. Results Source: 3. Results Source: 3. Results Source: 3. Results Source: 3. Results Source: 3. Results Source: 3. Results

Conclusions

This study found a clear dose: response relationship between daily Vit.D3 intake and path-VF risk. Patients with path-VF received significantly lower Vit.D3 doses than controls. The elevated risk observed in the Low-Dose group, particularly in those over 67.5 years, suggests that commonly recommended minimum doses may not provide sufficient protection. A threshold of approximately 1900 IU/day may be relevant for risk reduction in elderly patients.

These effects are unlikely to result solely from improvements in BMD but may instead reflect broader physiological benefits of adequate Vit.D3 availability, including contributions to muscle strength, metabolic balance, and reduced inflammation. Overall, these findings highlight the potential value of tailored Vit.D3 supplementation strategies in spinal surgery patients at elevated risk of vertebral fragility. Further prospective studies with larger cohorts and systematic monitoring of serum 25(OH)D levels are needed to define and validate clinically relevant dosing thresholds.

Source: 6. Conclusions Source: 6. Conclusions
Authors’ abstract

Background/Objectives:

Vitamin D deficiency contributes to pathological vertebral fragility (path-VF), including fragility fractures and early pedicle screw loosening after posterior instrumented spinal fusion (PISF). Supplementation practices remain inconsistent. This retrospective study evaluated whether patients with path-VF receive appropriate vitamin D3 (Vit.D3) supplementation and assessed the dose: response relationship between daily intake and path-VF risk, particularly in older adults.

Methods:

A total of 210 patients treated with kyphoplasty or PISF (2022 to 2023) were classified into a path-VF or control group. Daily oral Vit.D3 intake was categorised as Zero: (0 IU), Low: (<2000 IU), or High-Dose (≥2000 IU). Statistical analyses were performed for each dosage group, including subgroup analyses for patients aged ≥67.5 years. Vertebral BMD was estimated using mean Hounsfield Units (HU) from T11: L5.

Results:

Patients in the path-VF group received significantly lower Vit.D3 doses than controls (1431.4 ± 1055.7 vs. 2366.7 ± 1186.7 IU/day, p < 0.001). Low-dose supplementation was associated with a markedly increased risk of path-VF compared with high-dose in the overall cohort (OR = 6.5, p = 0.003) and in patients aged ≥67.5 years (OR = 8.6, p = 0.008). Logistic regression identified a threshold of 1900 IU/day (AUC = 0.805). Mean vertebral HU values were significantly lower in the path-VF group than in controls (71.9 ± 29.1 vs. 133.5 ± 52.6, p < 0.001), and no consistent HU gains were observed with increasing Vit.D3 dosage.

Conclusions:

Low-dose Vit.D3 supplementation was associated with increased path-VF risk, especially in patients aged >67.5 years. Patients without path-VF had received significantly higher doses, suggesting broader benefits of adequate Vit.D3 beyond bone density. A daily intake above 1900 IU may serve as a practical threshold for at-risk elderly patients.

Read the full paper

1. Introduction

Vitamin D (Vit.D) deficiency is a well-recognised risk factor for impaired spinal health and is closely associated with pathological vertebral fragility (path-VF). It increases the risk of fragility fractures (FF) [1], delays postoperative recovery and physical rehabilitation [2], reduces spinal fusion success rates [3], and contributes to implant-related complications such as early pedicle screw loosening (PSL). Despite its clinical relevance, the risks of path-VF are often insufficiently assessed in clinical practice prior to posterior instrumented spinal fusion (PISF).

Only 44% of spine surgeons perform preoperative bone mineral density (BMD) evaluations, and just 12% assess metabolic laboratory parameters, including 25-hydroxyvitamin-D (25(OH)D), parathyroid hormone, and calcium levels [4].

Although the above considerations support the role of Vit.D, perioperative supplementation in bone surgeries, especially in spine surgery, has shown inconsistent results. Some study reported improved fusion rates, symptom relief, and recovery despite small sample sizes [3]. Others, show no clear postoperative benefits and no consistent dose: response relationship [5,6]. Similar inconsistencies are seen in broader orthopedic research, often limited by heterogeneous designs and low methodological quality [7,8].

The biomechanical integrity of the vertebrae is maintained through dynamic bone remodelling, adapting to internal and external influences such as ageing, nutrition, biomechanical stress, menopause, chronic inflammatory conditions, and other systemic disorders [9,10]. Disruption of this osteogenic: osteoclastic balance significantly reduces BMD, predisposing vertebrae to fragility and increasing the risk of path-VF [11]. Vit.D is crucial for bone development and mechanical strength, facilitating calcium and phosphate metabolism [12,13]. Among available Vit.D supplements, vitamin D3 (Vit.D3) demonstrates superior efficacy in elevating serum 25(OH)D concentrations compared with vitamin D2 (Vit.D2) [14].

Existing international guidelines for Vit.D3 supplementation in adults vary widely in both age grouping and dosage and often provide ambiguous recommendations regarding target populations (typically limited to categories such as infants, children, adults, and pregnant or lactating women), initiation timing, and optimal dosage. Some countries make no age distinction for adults, while others introduce multiple age categories but recommend almost identical adequate intake levels [15,16,17,18,19]. Internationally [15,16,17,18,19], daily doses range from as low as 9 μg (360 IU) to as high as 100 μg (4000 IU).

This discrepancy fosters subjective decision-making in clinical practice, frequently overlooking certain patient groups (particularly males) and leading to arbitrary dosing within this broad range.

This study was performed to evaluate Vit.D3 supplementation in spinal surgery patients and to determine whether those at risk of path-VF (including FF and early PSL following PISF) receive appropriate supplementation compared with those without such risk. In addition, this study sought to identify specific cut-off values for age and daily Vit.D3 dosage that may guide supplementation strategies. The findings may provide evidence to refine clinical guidelines for Vit.D3 supplementation, with the aim of reducing the incidence of path-VF and its associated complications in spinal surgery patients.

2. Materials and Methods

2.1. Patients

In this retrospective case: control study, we evaluated 210 patients who underwent spinal surgical treatments, including balloon kyphoplasty and PISF, in the thoracic and lumbar regions at a single spine centre between 2022 and 2023.

2.2. Definitions of Path-VF and Early PSL

For this study, the diagnostic criteria for path-VF were based on the framework established in a previous study [20], with adaptations to the present research context. A diagnosis of path-VF was considered if any of the following conditions were met, after histological exclusion of tumour-related fractures:

  • (1)

    cases requiring balloon kyphoplasty for path-VF,

  • (2)

    intraoperative use of cement-augmented pedicle screws during the first PISF, or

  • (3)

    occurrence of non-traumatic PSL within 6 months after the initial PISF in the absence of prior screw reinforcement.

The indications for PISF in this study included severe degenerative lumbar stenosis with instability, idiopathic scoliosis, advanced spondylolisthesis, and de novo lumbar scoliosis. Patients with spondylodiscitis or spinal tumours were excluded.

Among the available techniques for enhancing screw fixation in osteoporotic vertebrae, cement augmentation is regarded as the most widely used and effective [21,22]. Therefore, only cement-augmented screws were used in the present cohort, while other reinforcement options (e.g., expandable screws, specialised thread designs, or bioactive-coated implants) were excluded.

The decision to perform screw reinforcement was made by senior spine surgeons following thorough preoperative assessment. Consistent with earlier findings, early PSL (<6 months) is predominantly associated with low BMD and reduced bone quality [23], whereas later PSL (>1 year) is more often related to mechanical overload, adjacent segment degeneration, suboptimal implant positioning, or chronic low-grade infection [24,25,26]. Based on these considerations, a 6-month threshold was applied in this study to define early PSL.

PSL was diagnosed using computed tomography (CT) imaging based on either a radiolucent rim > 1 mm around the screw or signs of screw pull-out/cut-out [26]. To reduce radiation exposure and costs, CT was limited to patients with severe symptoms such as intense localised pain or significant activity restriction [27].

2.3. Grouping

Patients were classified into two cohorts: the path-VF group, comprising individuals diagnosed with path-VF, and the control group, comprising patients without evidence of path-VF. Preoperative demographic data, including age, sex, and daily Vit.D3 supplementation dosage, were recorded for all participants.

2.4. Categorisation of Vit.D3 Dosage

Data on vitamin D supplementation were retrieved from general practitioner medication records or, when unavailable, collected during preoperative patient interviews.

To assess the impact of daily Vit.D3 intake, patients were categorised into three dosage groups: Zero-Dose (0 IU/day), Low-Dose (<2000 IU/day), and High-Dose (≥2000 IU/day). Patients whose Vit.D3 supplementation dosage changed between the PISF and the 6-month follow-up were excluded from the analysis.

Based on our previous study [20], which identified 67.5 years as the optimal age threshold for predicting path-VF risk, analyses were performed for the overall cohort and further stratified into subgroups above and below this threshold to examine the relationship between Vit.D3 intake and path-VF risk.

2.5. Measurement of Vertebral Hounsfield Units (HU)

To validate the definition of path-VF used in this study and to confirm the robustness of the subsequent grouping, vertebral bone quality was assessed using preoperative CT-based HU measurements. Among the 210 patients, only 8 had dual-energy X-ray absorptiometry (DEXA) results available before surgery. Preoperative lumbar spine CT scans were retrospectively evaluated in 88 patients. HU values were measured from Th11 to L5 using elliptical region of interest placed in the cancellous bone between the upper and middle thirds of each vertebral body, excluding cortical areas.

Regions containing vascular structures, Schmorl’s nodes, sclerosis, or tumorous changes were excluded. For each patient, the mean HU value from Th11 to L5 was calculated and used in subsequent analyses.

2.6. Statistical Analysis

All statistical analyses were conducted using R software version 4.4.1, 14 June 2024 (The R Foundation for Statistical Computing, Vienna, Austria). Continuous variables are reported as mean ± standard deviation, and statistical significance was defined as a two-tailed p-value of <0.05.

To compare means of numeric variables, the data normality was assessed previously using the Shapiro: Wilk test and Kolmogorov: Smirnov test, and variance homogeneity was verified using Levene’s test and the F-test. Due to non-normality, variance inhomogeneity, or limited sample size, group comparisons for age, daily Vit.D3 dosage, and HU values were performed using the Mann: Whitney U test. Effect sizes were reported as rank-biserial correlation coefficients (r), with r > 0.3 and r > 0.5 interpreted as medium and large effects, respectively.

Associations between Vit.D3 dosage categories and the risk of path-VF or path-VF with early PSL were examined using Fisher’s exact test, yielding odds ratios (ORs) with corresponding 95% confidence intervals (CIs).

To further explore potential predictors, multiple logistic regression was performed, incorporating sex, age, and Vit.D3 dosage categories (Zero-, Low-, and High-Dose) as independent variables. Multicollinearity among predictors was evaluated using variance inflation factors (VIF). A VIF < 5 was considered acceptable. Receiver operating characteristic (ROC) curve analysis was used to identify potential dosage thresholds, with an area under the curve (AUC) of ≥0.8 interpreted as indicating excellent discriminative ability.

3. Results

3.1. Demographics of the Study Cohort

The study cohort comprised 210 patients with a mean age of 67.5 years (range 18.5 to 87.9 years), including 80 males and 130 females. Of these, 84 patients were classified into the path-VF group and 126 into the control group. Osteoporosis was pre-diagnosed in 42 patients using DEXA or quantitative CT, of whom 13 did not take Vit.D3, 20 received a low dose, and 9 received a high dose. In total, 53 patients in the cohort received Vit.D3 supplementation at varying doses.

Detailed demographic characteristics are summarised in Table 1.

3.2. HU Values in the Path-VF and Control Groups

As expected, HU measurements confirmed the validity of the applied path-VF definition and the derived grouping. The path-VF group showed significantly lower mean vertebral HU values than did the control group (71.9 ± 29.1 vs. 133.5 ± 52.6, p < 0.001, r = 0.61), consistent with reduced bone quality in patients meeting the path-VF criteria.

3.3. Differences in Daily Doses of Vit.D3 Between the Path-VF and Control Groups

Oral daily Vit.D3 supplementation doses were compared between the path-VF and control groups using the Mann: Whitney U test. Patients in the path-VF group received significantly lower daily doses than those in the control group (Table 2).

Figure 1 illustrates the age distribution of Vit.D3 supplementation. Patients without Vit.D3 supplementation and without path-VF risk were spread across all age ranges. By contrast, those not receiving Vit.D3 but meeting the path-VF criteria for FF or early PSL were mainly observed from approximately 50 years of age onwards. The previously established age threshold for path-VF risk (67.5 years) [20] is indicated by a vertical dashed line. Among patients receiving Vit.D3, daily doses below 2000 IU were predominantly found in the path-VF group, particularly in individuals above the 67.5-year threshold.

By comparison, only 6 of 33 patients in the control group fell into this low-dose category. Conversely, most patients receiving ≥ 2000 IU/day (12 of 20) were in the control group and showed no path-VF risk.

3.4. ORs of Oral Vit.D3 Dosages for Path-VF Risk

ORs for different oral Vit.D3 dosage categories and path-VF risk were calculated for the overall cohort (n = 210) and for the subgroup of patients aged >67.5 years (Figure 2), with diagnosed osteoporosis serving as a positive control.

As expected, osteoporosis was significantly associated with increased path-VF risk in both the overall cohort (OR: 14.8, 95% CI [5.7 to 45.7], p < 0.001) and the older subgroup (OR: 6.4, 95% CI [2.3 to 20.9], p < 0.001). The Vit.D3 dosage showed similar patterns in both analyses. Compared with patients taking Low-Dose Vit.D3, those in the Zero-Dose category had a significantly lower path-VF risk in the overall cohort (OR: 0.10, 95% CI [0.03 to 0.27], p < 0.001) and in the older subgroup (OR: 0.11, 95% CI [0.02 to 0.43], p < 0.001).

This apparent lower risk in the Zero-Dose group than in the Low-Dose group will be further considered in the Discussion. Low-Dose supplementation was associated with a significantly higher path-VF risk than was High-Dose supplementation (overall OR: 6.5, 95% CI [1.6 to 28.9], p = 0.003; older subgroup OR: 8.6, 95% CI [1.6 to 64.2], p = 0.008). Zero-Dose versus High-Dose showed no significant association with path-VF (OR not different from 1; both p-values > 0.05).

Multiple logistic regression analysis assessed the associations between path-VF occurrence and age, sex, and daily Vit.D3 dosage (Zero-, Low-, and High-Dose). All predictors showed VIF values close to 1 (range: 1.00 to 1.07), indicating no evidence of multicollinearity. As shown in Table 3, female sex was positively but not significantly associated with path-VF risk (β = 0.64, p > 0.05). Higher daily Vit.D3 dosage was linked to a small yet statistically significant reduction in path-VF occurrence (β = −0.001, p = 0.018).

Increasing age was significantly associated with elevated path-VF risk (β = 0.08, p = 0.031). ROC analysis for daily Vit.D3 dosage identified a threshold of 1900 IU/day, yielding an AUC of 0.805 (Figure 3), indicating good predictive accuracy.

3.5. Effects of Different Vit.D3 Daily Doses on HU Values

Firstly, HU values in the path-VF group were significantly lower than in the control group (p < 0.001) (Figure 4A). The violin plots show that HU values for path-VF patients were concentrated below 100, whereas control patients displayed a broader distribution towards higher values. By contrast, patient age showed the opposite pattern (Figure 4B), with those in the path-VF group being older (74.6 ± 9.1 years) than those in the control group (63.7 ± 13.7 years, p < 0.001, r = 0.42).

We next examined the relationship between Vit.D3 dosage, HU values, and age. Mean HU values (Figure 5A) were 86.3 ± 37.9 (High-Dose, n = 11), 71.4 ± 27.4 (Low-Dose, n = 16), and 112.9 ± 55.7 (Zero-Dose, n = 61), with a statistically significant difference observed only between the Low-Dose and Zero-Dose groups (p = 0.004, r = 0.55). Corresponding mean ages (Figure 5B) were 70.3 ± 10.9, 76.9 ± 9.2, and 67.1 ± 13.2 years, respectively, with a significant difference again between the Low-Dose and Zero-Dose groups (p = 0.006, r = 0.53).

All comparisons involving the High-Dose group showed no statistically significant differences, with small effect sizes (r < 0.3), suggesting that the limited sample size may have contributed to the lack of significance.

4. Discussion

Vit.D is a fat-soluble vitamin that plays a central role in regulating calcium, magnesium, and phosphorus metabolism. Serum 25(OH)D measurement is the standard method for assessing Vit.D status, with concentrations above 30 ng/mL generally regarded as sufficient [28]. Ageing, menopause, and reduced outdoor activity further exacerbate chronic Vit.D deficiency [29], increasing the risk of osteoporosis, path-VF with associated FF, and postoperative complications following instrumented spinal fusion [3].

4.1. Clinical Relevance in Spinal Surgery

In spinal surgery, Vit.D inadequacy is defined as serum 25(OH)D levels of 20 to 30 ng/mL, and deficiency as levels of <20 ng/mL [30]. While approximately 30% of the general population have levels below 20 ng/mL [31], the prevalence is markedly higher among patients requiring surgical treatment, with up to 73.6% for levels below 30 ng/mL and 36.8% for levels below 20 ng/mL [32]. Deficiency is linked to worse preoperative symptom severity, reflected in higher Japanese Orthopaedic Association, visual analogue scale, and Oswestry Disability Index (ODI) scores [28,33,34].

It is also associated with poorer postoperative recovery [2,35], longer fusion times [36], and lower fusion success rates [3].

Perioperative Vit.D3 supplementation has shown potential benefits in symptom relief and functional recovery, yet existing studies remain inconsistent regarding optimal dosage, timing, and patient selection [8]. Ko et al. used intramuscular injections of 100,000 IU perioperatively without specifying frequency [35], while Xu et al. observed improved fusion rates and reduced ODI scores after PISF, though without clear details on dosage or duration [37]. Waikakul et al. administered 600 IU/day of Vit.D2 for 10 days followed by 600 IU/day of Vit.D3 for maintenance in failed back surgery syndrome, noting symptomatic improvement despite the small sample size [33].

A meta-analysis reported no benefit for fractures, falls, or BMD, with no difference observed between doses above or below 800 IU/day [38]. These mixed findings align with broader orthopedic literature, where Vit.D3 supplementation shows limited or inconsistent effects on fracture healing and clinical outcomes, with positive results often linked to lower-quality studies or lacking dose: response clarity [6,7,8].

4.2. Global Variability and Clinical Uncertainty

International guidelines for Vit.D3 supplementation differ substantially in both dosage and age-group definitions. Some make no age distinctions, while others define multiple age brackets but recommend nearly identical adequate intake levels. Across all guidelines, the gap between the adequate intake and the upper level of intake (4000 IU/day) remains large. This complicates clinical decisions, particularly for spinal surgeons managing patients at risk of path-VF. For example, the United States recommends 600 IU/day for adults aged 19 to 70 years and 800 IU/day for those aged ≥71 years [15].

The European Food Safety Authority advises 600 IU/day for all adults and sets an upper level of intake of 4000 IU/day, while the German osteoporosis S3 guideline recommends 800 IU/day, advising against exceeding 2000 to 4000 IU/day [16,17]. The UK sets a range of 400 to 4000 IU/day for all adults without age subdivision [18]. South Korea recommends 400 IU/day for adults aged 19 to 49 years and 600 IU/day for those aged ≥50 years, with an upper limit of 4000 IU/day [19].

Japan recommends 360 to 4000 IU/day for all adults, subdivided into multiple age categories [39]. Such variability fosters subjective prescribing practices and underscores the lack of evidence-based dosing thresholds, a concern that is particularly relevant for spinal surgery patients.

4.3. Dose: Response Relationship in the Present Study

In this study, daily Vit.D3 intake showed a clear dose: response association with the risk of path-VF. Patients receiving supplementation at the lower end of guideline-recommended ranges had a substantially higher risk of path-VF. Consistent with this, patients in the path-VF group had significantly lower daily doses than those in the control group, with median values of 1431.4 IU versus 2366.7 IU, respectively (Table 2). This elevated risk for the Low-Dose group was evident in both the overall cohort and among patients above the identified age threshold of 67.5 years, with ORs indicating several-fold differences.

The age distribution of supplementation in our cohort supports this interpretation because most patients in the path-VF group received around 1000 IU/day or less, particularly those above the threshold age, whereas higher-dose supplementation was more common among controls without path-VF. Based on this pattern, multiple logistic regression identified a threshold of approximately 1900 IU/day. One possible explanation is selection bias in supplementation practices; clinicians may preferentially initiate Vit.D3 at low doses without timely adjustment according to changes in the patient’s condition or individual needs.

The consistent dose: response trend indicates that low-dose regimens may be inadequate for high-risk patients. Doses above the threshold may help reduce vertebral fragility: related complications. However, as the identified threshold of approximately 1900 IU/day is based on retrospective data, prospective studies are needed to validate its clinical significance. Results from the High-Dose group should also be interpreted with caution, as the low rank-biserial correlation coefficients (r < 0.3) reflect limited statistical power due to small sample size. Additionally, the unexpectedly lower risk observed in the Zero-Dose group warrants careful interpretation and will be addressed separately.

4.4. Interpretation of Zero-Dose Patient Outcomes

The observed ORs below 1 in the Zero-Dose group should be interpreted cautiously and are unlikely to reflect a true protective effect of no supplementation. A more likely explanation is ‘healthy user’ bias, where these patients may have better bone quality, fewer comorbidities, or higher physical activity, even at older ages [40,41].

Structural changes associated with ageing, such as Modic changes, endplate sclerosis, and intervertebral osteophyte fusion, may also contribute to increased vertebral stiffness and improved screw stability. Wagnac et al. demonstrated that large osteophytes can enhance vertebral rigidity and reduce fracture susceptibility [42], while Modic-related sclerosis has been shown to increase HU values and prevent cage subsidence [43,44].

The benefit in the Zero-Dose group likely reflects selection bias and structural adaptations, though this remains speculative without objective health data.

4.5. Effect of Vit.D3 on HU Values of Vertebrae

At this stage of the analysis, we further explored whether the increased risk observed in the Low-Dose group could be explained by lower vertebral BMD assessed through HU measurements, and whether HU values differed systematically across the three dosage categories (Zero, Low, High). As expected, HU values were significantly lower in patients with path-VF than in controls, confirming their role as a surrogate marker of bone fragility and screw stability [45].

When analysing HU values across dosage categories, we observed that patients receiving Low-Dose Vit.D3 indeed showed lower HU values and were older than those without supplementation, whereas patients on High-Dose Vit.D3 displayed intermediate HU values without statistical significance. This finding is consistent with earlier clinical trials showing that low daily doses of Vit.D3, typically below 800 to 1000 IU, fail to improve BMD at the lumbar spine or hip [38,46], and that even moderate doses around 900 IU did not yield significant BMD increases in postmenopausal women [47,48].

These results suggest that while low-dose supplementation may be insufficient to counteract age-related BMD decline, higher doses do not necessarily translate into measurable HU gains either. The significant difference in Vit.D3 intake between path-VF and control groups (Table 2) therefore indicates that the observed clinical association is more closely related to overall dose adequacy. The apparent benefit of sufficient supplementation is likely to involve additional mechanisms beyond direct increases in vertebral BMD, such as modulation of bone metabolism, muscle function, or inflammatory pathways.

4.6. Potential Mechanisms of Vit.D in Preventing Path-VF Risk

The protective association of Vit.D3 observed in this study is unlikely to be mediated solely through increases in vertebral BMD. Instead, several additional biological mechanisms may contribute to the reduced path-VF risk. Beyond its established skeletal effects, Vit.D is involved in diverse physiological processes, including immune regulation, cardiovascular function, endocrine balance, and metabolic pathways. It has also been reported to alleviate pain, improve mood, and influence recovery after surgery [49].

One important pathway is through muscle function. Vit.D enhances muscle strength and balance, thereby lowering fall risk, a key determinant of fracture occurrence. This effect is mediated by Vit.D receptors in muscle cells, which regulate protein synthesis and calcium uptake [50]. Age-related declines in Vit.D receptor expression may precede structural bone changes, but Vit.D-related muscle weakness (hypovitaminosis D myopathy) can be reversed with adequate supplementation [51]. Clinical evidence supports this indirect protective effect, with studies showing that Vit.D supplementation reduces fall rates in older adults [52].

Vit.D also modulates parathyroid hormone activity, which is central to bone metabolism. Persistent Vit.D deficiency can lead to secondary hyperparathyroidism, causing elevated bone turnover and cortical bone loss. Pfeifer et al. demonstrated that Vit.D3 combined with calcium supplementation reduces parathyroid hormone levels in elderly women and improves balance, thereby decreasing fracture risk [53].

Finally, Vit.D exerts immunomodulatory and anti-inflammatory effects. It reduces circulating proinflammatory cytokines such as interleukin-6, interleukin-8, and tumour necrosis factor, which are known to impair bone homeostasis and hinder surgical recovery [54]. AlGhamdi et al. showed that high-dose monthly Vit.D3 administration (80,000 IU, approximately 2666 IU/day) significantly decreased these cytokines [55]. Such effects may not only contribute to fracture prevention but also enhance postoperative recovery and reduce complications such as cage subsidence or PSL after spinal procedures.

Taken together, these pleiotropic actions of Vit.D3 reinforce its clinical relevance in spinal surgery patients, particularly when direct improvements in vertebral bone density are not consistently measurable.

5. Limitations

This study has several limitations. First, its retrospective design limits the ability to establish causality between Vit.D3 dosage and path-VF occurrence. Second, serum 25(OH)D levels were not routinely assessed, preventing correlation analyses between measured Vit.D status and clinical outcomes. Third, the sample size in the High-Dose group was relatively small, which may have reduced the statistical power to detect significant associations.

Finally, other confounding factors, such as comorbidities, nutritional status, or physical activity levels, were not systematically controlled and may have influenced the observed relationships. In particular, the absence of objective health-status indicators introduces a potential ‘healthy user’ bias in the Zero-Dose group, meaning that their apparently lower risk may partly reflect better baseline physiological reserve rather than a true protective effect of no supplementation.

6. Conclusions

This study found a clear dose: response relationship between daily Vit.D3 intake and path-VF risk. Patients with path-VF received significantly lower Vit.D3 doses than controls. The elevated risk observed in the Low-Dose group, particularly in those over 67.5 years, suggests that commonly recommended minimum doses may not provide sufficient protection. A threshold of approximately 1900 IU/day may be relevant for risk reduction in elderly patients.

These effects are unlikely to result solely from improvements in BMD but may instead reflect broader physiological benefits of adequate Vit.D3 availability, including contributions to muscle strength, metabolic balance, and reduced inflammation. Overall, these findings highlight the potential value of tailored Vit.D3 supplementation strategies in spinal surgery patients at elevated risk of vertebral fragility. Further prospective studies with larger cohorts and systematic monitoring of serum 25(OH)D levels are needed to define and validate clinically relevant dosing thresholds.

Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Author Contributions

Conceptualization, J.L.; methodology, J.L. and A.S.; software, J.L.; validation, J.L., A.S. and M.D.; formal analysis, J.L. and A.S.; investigation, J.L.; resources, B.K., S.K. and M.D.; data curation, J.L. and M.D.; writing: original draft preparation, J.L.; writing: review and editing, J.L., A.S., M.S., L.V., P.S. and M.D.; visualization, J.L.; supervision, M.S., L.V., P.S. and M.D.; project administration, M.D.; funding acquisition, M.D. All authors have read and agreed to the published version of the manuscript.

Institutional Review Board Statement

The study was conducted in accordance with the Declaration of Helsinki and approved by the Institutional Review Board of RKH Orthopaedic Hospital Markgröningen (protocol code: 2023_04, approved on 15 October 2023, protocol code: 2025_NO_04, approved on 29 September 2025).

Informed Consent Statement

Informed consent was not required for this retrospective study using anonymized patient data, as approved by the institutional review board.

Data Availability Statement

The datasets generated and/or analysed during the current study are not publicly available due to institutional data ownership. The data are the property of RKH Orthopaedic Clinic Markgröningen, 71706 Markgröningen, Baden-Württemberg, Germany. Data may be made available upon reasonable request and with prior approval from the institution. Requests should be directed to the corresponding author.

Conflicts of Interest

The authors declare no conflicts of interest.

Abbreviations

The following abbreviations are used in this manuscript: 25(OH)D25-hydroxyvitamin-DAUCArea under the curveBMDBone mineral densityCIConfidence intervalsCTComputed tomographyDEXADual-energy X-ray absorptiometryFFFragility fracturesHUHounsfield unitsODIOswestry disability indexOROdds RatioPath-VFPathological vertebral fragilityPISFPosterior instrumented spinal fusionPSLPedicle screw looseningROCReceiver operating characteristic curveSDStandard deviationSEStandard errorVFVertebral fragilityVIFVariance inflation factorsVit.DVitamin DVit.D2Vitamin D2Vit.D3Vitamin D3

References

1. Maier G.S. Seeger J.B. Horas K. Roth K.E. Kurth A.A. Maus U. The prevalence of vitamin D deficiency in patients with vertebral fragility fractures Bone Jt. J. 2015 97 89 93 10.1302/0301-620X.97B1.34558 25568419
2. Xu H.W. Shen B. Hu T. Zhao W.-D. Wu D.-S. Wang S.-J. Preoperative vitamin D status and its effects on short-term clinical outcomes in lumbar spine surgery J. Orthop. Sci. 2020 25 787 792 10.1016/j.jos.2019.10.011 31759837
3. Hu M.H. Tseng Y.-K. Chung Y.-H. Wu N.-Y. Li C.-H. Lee P.-Y. The efficacy of oral vitamin D supplements on fusion outcome in patients receiving elective lumbar spinal fusion-a randomized control trial BMC Musculoskelet. Disord. 2022 23 996 10.1186/s12891-022-05948-9 36401234 PMC9673414
4. Dipaola C.P. Bible J.E. Biswas D. Dipaola M. Grauer J.N. Rechtine G.R. Survey of spine surgeons on attitudes regarding osteoporosis and osteomalacia screening and treatment for fractures, fusion surgery, and pseudoarthrosis Spine J. 2009 9 537 544 10.1016/j.spinee.2009.02.005 19328744
5. Donnally C.J. Sheu J.I. Bondar K.J. Mouhanna J.N. Li D.J. Butler A.J. Rush A.J. Gjolaj J.P. Is There a Correlation Between Preoperative or Postoperative Vitamin D Levels with Pseudarthrosis, Hardware Failure, and Revisions After Lumbar Spine Fusion World Neurosurg. 2019 130 e431 e437 10.1016/j.wneu.2019.06.109 31238168
6. Slobogean G.P. Bzovsky S. O’HAra N.N. Marchand L.S. Hannan Z.D. Demyanovich H.K. Connelly D.W. Adachi J.D. Thabane L. Sprague S. Effect of Vitamin D3 Supplementation on Acute Fracture Healing: A Phase II Screening Randomized Double-Blind Controlled Trial JBMR Plus 2023 7 e10705 10.1002/jbm4.10705 36699638 PMC9850434
7. Gatt T. Grech A. Arshad H. The Effect of Vitamin D Supplementation for Bone Healing in Fracture Patients: A Systematic Review Adv. Orthop. 2023 2023 6236045 10.1155/2023/6236045 36895823 PMC9991484
8. Mayo B.C. Massel D.H. Yacob A. Narain A.S. Hijji F.Y. Jenkins N.W. Parrish J.M. Modi K.D. Long W.W. Hrynewycz N.M. A Review of Vitamin D in Spinal Surgery: Deficiency Screening, Treatment, and Outcomes Int. J. Spine Surg. 2020 14 447 454 10.14444/7059 32699770 PMC7343270
9. Singh S. Sarma D.K. Verma V. Nagpal R. Kumar M. From Cells to Environment: Exploring the Interplay between Factors Shaping Bone Health and Disease Medicina 2023 59 1546 10.3390/medicina59091546 37763665 PMC10532995
10. Castañeda S. Ceballos C.N. Jaeger J.U. Benadiba C.d.M. Martín E.G. Díaz-Guerra G.M. Alvarez-Galovich L. Management of Vertebral Fragility Fracture in Older People: Recommendations from a Spanish Consensus of Experts Geriatrics 2024 9 24 10.3390/geriatrics9020024 38525741 PMC10961758
11. Al-Bari A.A. Al Mamun A. Current advances in regulation of bone homeostasis FASEB Bioadv. 2020 2 668 679 10.1096/fba.2020-00058 33205007 PMC7655096
12. Demontiero O. Vidal C. Duque G. Aging and bone loss: New insights for the clinician Ther. Adv. Musculoskelet. Dis. 2012 4 61 76 10.1177/1759720X11430858 22870496 PMC3383520
13. Sornay-Rendu E. Duboeuf F. Chapurlat R.D. Postmenopausal women with normal BMD who have fractures have deteriorated bone microarchitecture: A prospective analysis from The OFELY study Bone 2024 182 117072 10.1016/j.bone.2024.117072 38492712
14. van den Heuvel E.G. Lips P. Schoonmade L.J. Lanham-New S.A. van Schoor N.M. Comparison of the Effect of Daily Vitamin D2 and Vitamin D3 Supplementation on Serum 25-Hydroxyvitamin D Concentration (Total 25(OH)D, 25(OH)D2, and 25(OH)D3) and Importance of Body Mass Index: A Systematic Review and Meta-Analysis Adv. Nutr. 2024 15 100133 10.1016/j.advnut.2023.09.016 37865222 PMC10831883
15. Demay M.B. Pittas A.G. Bikle D.D. Diab D.L. Kiely M.E. Lazaretti-Castro M. Lips P. Mitchell D.M. Murad M.H. Powers S. Vitamin D for the Prevention of Disease: An Endocrine Society Clinical Practice Guideline J. Clin. Endocrinol. Metab. 2024 109 1907 1947 10.1210/clinem/dgae290 38828931
16. Gesellschafte D.W.O. DVO-Leitlinie (2023) Leitlinie des Dachverbands der Deutschsprachigen Wissenschaftlichen Osteologischen Gesellschaften 2023: Prophylaxe, Diagnostik und Therapie der Osteoporose Available online: https://register.awmf.org/assets/guidelines/183-001l_S3_Prophylaxe-Diagnostik-Therapie-der-Osteoporose_2023-11.pdf(accessed on 9 August 2025)
17. EFSA Panel on Nutrition Novel Foods and FoodAllergens (NDA) Turck D. Bohn T. Castenmiller J. de Henauw S. Hirsch-Ernst K.-I. Knutsen H.K. Maciuk A. Mangelsdorf I. Scientific opinion on the tolerable upper intake level for vitamin D, including the derivation of a conversion factor for calcidiol monohydrate EFSA J. 2023 21 e08145 10.2903/j.efsa.2023.8145 37560437 PMC10407748
18. National Institutes of Health National Institute of Occupational Health Vitamins and Minerals: Vitamin D 2025 Available online: https://www.nhs.uk/conditions/vitamins-and-minerals/vitamin-d/(accessed on 9 August 2025)
19. Kim J.H. Park H.S. Pae M. Park K.H. Kwon O. Evidence and suggestions for establishing vitamin D intake standards in Koreans for the prevention of chronic diseases Nutr. Res. Pract. 2022 16 S57 S69 10.4162/nrp.2022.16.S1.S57 35651832 PMC9127520
20. Li J. Strahl A. Kunze B. Krebs S. Stangenberg M. Viezens L. Strube P. Dreimann M. Ageing and BMI in Focus: Rethinking Risk Assessment for Vertebral Fragility and Pedicle Screw Loosening in Older Adults J. Clin. Med. 2025 14 5296 10.3390/jcm14155296 40806918 PMC12347785
21. Boucas P. Mamdouhi T. Rizzo S.E. Megas A. Cement Augmentation of Pedicle Screw Instrumentation: A Literature Review Asian Spine J. 2023 17 939 948 10.31616/asj.2022.0216 37788974 PMC10622820
22. Song Z. Zhou Q. Jin X. Zhang J. Cement-augmented pedicle screw for thoracolumbar degenerative diseases with osteoporosis: A systematic review and meta-analysis J. Orthop. Surg. Res. 2023 18 631 10.1186/s13018-023-04077-w 37641101 PMC10464480
23. Weiser L. Huber G. Sellenschloh K. Viezens L. Püschel K. Morlock M.M. Lehmann W. Insufficient stability of pedicle screws in osteoporotic vertebrae: Biomechanical correlation of bone mineral density and pedicle screw fixation strength Eur. Spine J. 2017 26 2891 2897 10.1007/s00586-017-5091-x 28391382
24. Leitner L. Malaj I. Sadoghi P. Amerstorfer F. Glehr M. Vander K. Leithner A. Radl R. Pedicle screw loosening is correlated to chronic subclinical deep implant infection: A retrospective database analysis Eur. Spine J. 2018 27 2529 2535 10.1007/s00586-018-5592-2 29654369
25. Kim J.B. Park S.-W. Lee Y.-S. Nam T.-K. Park Y.-S. Kim Y.-B. The Effects of Spinopelvic Parameters and Paraspinal Muscle Degeneration on S1 Screw Loosening J. Korean Neurosurg. Soc. 2015 58 357 362 10.3340/jkns.2015.58.4.357 26587190 PMC4651997
26. Marie-Hardy L. Pascal-Moussellard H. Barnaba A. Bonaccorsi R. Scemama C. Screw Loosening in Posterior Spine Fusion: Prevalence and Risk Factors Glob. Spine J. 2020 10 598 602 10.1177/2192568219864341 32677565 PMC7359691
27. Galbusera F. Volkheimer D. Reitmaier S. Berger-Roscher N. Kienle A. Wilke H.-J. Pedicle screw loosening: A clinically relevant complication Eur. Spine J. 2015 24 1005 1016 10.1007/s00586-015-3768-6 25616349
28. Bajaj A. Shah R.M. Goodwin A.M. Kurapaty S. Patel A.A. Divi S.N. The Role of Preoperative Vitamin D in Spine Surgery Curr. Rev. Musculoskelet. Med. 2023 16 48 54 10.1007/s12178-022-09813-z 36538281 PMC9889582
29. Khodabakhshi A. Davoodi S.H. Vahid F. Vitamin D status, including serum levels and sun exposure are associated or correlated with bone mass measurements diagnosis, and bone density of the spine BMC Nutr. 2023 9 48 10.1186/s40795-023-00707-y 36918953 PMC10013235
30. Stoker G.E. Buchowski J.M. Bridwell K.H. Lenke L.G. Riew K.D. Zebala L.P. Preoperative vitamin D status of adults undergoing surgical spinal fusion Spine 2013 38 507 515 10.1097/BRS.0b013e3182739ad1 22986835
31. Rodriguez W.J. Gromelski J. Vitamin d status and spine surgery outcomes ISRN Orthop. 2013 2013 471695 10.1155/2013/471695 24959360 PMC4045309
32. Schmidt T. Ebert K. Rolvien T. Oehler N. Lohmann J. Papavero L. Kothe R. Amling M. Barvencik F. Mussawy H. A retrospective analysis of bone mineral status in patients requiring spinal surgery BMC Musculoskelet. Disord. 2018 19 53 10.1186/s12891-018-1970-5 29439698 PMC5811985
33. Waikakul S. Serum 25-hydroxy-calciferol level and failed back surgery syndrome J. Orthop. Surg. 2012 20 18 22 10.1177/230949901202000104 22535805
34. Kim T.H. Yoon J.Y. Lee B.H. Jung H.-S. Park M.S. Park J.-O. Moon E.-S. Kim H.-S. Lee H.-M. Moon S.-H. Changes in vitamin D status after surgery in female patients with lumbar spinal stenosis and its clinical significance Spine 2012 37 E1326 E1330 10.1097/BRS.0b013e318268ff05 22805343
35. Ko S. Chae S. Choi W. Kwon J. Choi J.Y. The effectiveness of vitamin D supplementation in functional outcome and quality of life (QoL) of lumbar spinal stenosis (LSS) requiring surgery J. Orthop. Surg. Res. 2020 15 117 10.1186/s13018-020-01629-2 32209124 PMC7092593
36. Ravindra V.M. Godzik J. Guan J. Dailey A.T. Schmidt M.H. Bisson E.F. Hood R.S. Ray W.Z. Prevalence of Vitamin D Deficiency in Patients Undergoing Elective Spine Surgery: A Cross-Sectional Analysis World Neurosurg. 2015 83 1114 1119 10.1016/j.wneu.2014.12.031 25535064
37. Xu Y. Zhou M. Liu H. Zhang Q. Hu Z. Zhang N. Ren Y. Effect of 1,25-dihydroxyvitamin D3 on posterior transforaminal lumbar interbody fusion in patients with osteoporosis and lumbar disc degenerative disease Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi 2014 28 969 972 25417309
38. Bolland M.J. Grey A. Avenell A. Effects of vitamin D supplementation on musculoskeletal health: A systematic review, meta-analysis, and trial sequential analysis Lancet Diabetes Endocrinol. 2018 6 847 858 10.1016/S2213-8587(18)30265-1 30293909
39. Ministry of Health, Labour and Welfare, Japan Dietary Reference Intakes for Japanese 2025 Available online: https://www.dobun.co.jp/scbookdata/stofcj2025.pdf(accessed on 9 August 2025)(In Japanese)
40. Albrecht B.M. Stalling I. Foettinger L. Recke C. Bammann K. Adherence to Lifestyle Recommendations for Bone Health in Older Adults with and without Osteoporosis: Cross-Sectional Results of the OUTDOOR ACTIVE Study Nutrients 2022 14 2463 10.3390/nu14122463 35745193 PMC9228189
41. Pinheiro M.B. Oliveira J. Bauman A. Fairhall N. Kwok W. Sherrington C. Evidence on physical activity and osteoporosis prevention for people aged 65+ years: A systematic review to inform the WHO guidelines on physical activity and sedentary behaviour Int. J. Behav. Nutr. Phys. Act. 2020 17 150 10.1186/s12966-020-01040-4 33239014 PMC7690138
42. Wagnac E. Aubin C. Chaumoître K. Mac-Thiong J.-M. Ménard A.-L. Petit Y. Garo A. Arnoux P.-J. Substantial vertebral body osteophytes protect against severe vertebral fractures in compression PLoS ONE 2017 12 e0186779 10.1371/journal.pone.0186779 29065144 PMC5655488
43. Liu J. Huang B. Hao L. Shan Z. Zhang X. Chen J. Fan S. Zhao F. Association between Modic changes and endplate sclerosis: Evidence from a clinical radiology study and a rabbit model J. Orthop. Translat 2019 16 71 77 10.1016/j.jot.2018.07.006 30723683 PMC6350022
44. Liu J. Ding W. Yang D. Wu H. Hao L. Hu Z. Fan S. Zhao F. Modic Changes (MCs) Associated with Endplate Sclerosis Can Prevent Cage Subsidence in Oblique Lumbar Interbody Fusion (OLIF) Stand-Alone World Neurosurg. 2020 138 e160 e168 10.1016/j.wneu.2020.02.047 32081816
45. Zaidi Q. MacNeille R. Ramos O. Wycliffe N. Danisa O. İnCeoğlu S. Cheng W. Predicting Pedicle Screw Pullout and Fatigue Performance: Comparing Lateral Dual-Energy X-Ray Absorptiometry, Anterior to Posterior Dual-Energy X-Ray Absorptiometry, and Computed Tomography Hounsfield Units Int. J. Spine Surg. 2023 17 43 50 10.14444/8356 36805550 PMC10025856
46. Reid I.R. Bolland M.J. Grey A. Effects of vitamin D supplements on bone mineral density: A systematic review and meta-analysis Lancet 2014 383 146 155 10.1016/S0140-6736(13)61647-5 24119980
47. Jackson R.D. LaCroix A.Z. Gass M. Wallace R.B. Robbins J. Lewis C.E. Bassford T. Beresford S.A. Black H.R. Blanchette P. Calcium plus vitamin D supplementation and the risk of fractures N. Engl. J. Med. 2006 354 669 683 10.1056/NEJMoa055218 16481635
48. LeBoff M.S. Chou S.H. Murata E.M. Donlon C.M. Cook N.R. Mora S. Lee I.-M. Kotler G. Bubes V. Buring J.E. Effects of Supplemental Vitamin D on Bone Health Outcomes in Women and Men in the VITamin D and OmegA-3 TriaL (VITAL) J. Bone Miner. Res. 2020 35 883 893 10.1002/jbmr.3958 31923341 PMC7217747
49. Ellison D.L. Moran H.R. Vitamin D: Vitamin or Hormone Nurs. Clin. N. Am. 2021 56 47 57 10.1016/j.cnur.2020.10.004 33549285
50. Bouillon R. Marcocci C. Carmeliet G. Bikle D. White J.H. Dawson-Hughes B. Lips P. Munns C.F. Lazaretti-Castro M. Giustina A. Skeletal and Extraskeletal Actions of Vitamin D: Current Evidence and Outstanding Questions Endocr. Rev. 2019 40 1109 1151 10.1210/er.2018-00126 30321335 PMC6626501
51. Glerup H. Mikkelsen K. Poulsen L. Hass E. Overbeck S. Andersen H. Charles P. Eriksen E.F. Hypovitaminosis D myopathy without biochemical signs of osteomalacic bone involvement Calcif. Tissue Int. 2000 66 419 424 10.1007/s002230010085 10821877
52. Bischoff-Ferrari H.A. Dawson-Hughes B. Staehelin H.B. Orav J.E. E Stuck A. Theiler R. Wong J.B. Egli A. Kiel D.P. Henschkowski J. Fall prevention with supplemental and active forms of vitamin D: A meta-analysis of randomised controlled trials BMJ 2009 339 b3692 10.1136/bmj.b3692 19797342 PMC2755728
53. Pfeifer M. Begerow B. Minne H.W. Abrams C. Nachtigall D. Hansen C. Effects of a short-term vitamin D and calcium supplementation on body sway and secondary hyperparathyroidism in elderly women J. Bone Miner. Res. 2000 15 1113 1118 10.1359/jbmr.2000.15.6.1113 10841179
54. Prietl B. Treiber G. Pieber T.R. Amrein K. Vitamin D and immune function Nutrients 2013 5 2502 2521 10.3390/nu5072502 23857223 PMC3738984
55. AlGhamdi S.A. Enaibsi N.N. Alsufiani H.M. Alshaibi H.F. Khoja S.O. Carlberg C. A Single Oral Vitamin D3 Bolus Reduces Inflammatory Markers in Healthy Saudi Males Int. J. Mol. Sci. 2022 23 11992 10.3390/ijms231911992 36233290 PMC9569869
Figure 1

Distribution of daily vitamin D3 supplementation by age group and dosage category. Each dot represents an individual patient, with red circles indicating patients in the path-VF group and blue triangles indicating controls. The vertical dashed line marks the path-VF age threshold at 67.5 years. Vitamin D3 supplementation is categorized into Zero Dose (0 IU/day), Low Dose (<2000 IU/day), and High Dose (≥2000 IU/day). Numbers of patients per subgroup are indicated for both path-VF and control groups.

Figure image at the original source: open the original paper. This file is not included in this text import.
Figure 2

Forest plot of odds ratios (ORs) for path-VF risk across Vit.D3 dosage groups. ORs with 95% confidence intervals and p-values are shown for comparisons among Zero-, Low-, and High-Dose vitamin D3 groups in the overall cohort and in patients aged over 67.5 years. ORs are displayed on a log10 scale.

Figure image at the original source: open the original paper. This file is not included in this text import.
Figure 3

ROC curve identifying 1900 IU/day as the threshold of daily Vit.D3 intake for predicting path-VF (AUC = 0.805).

Figure image at the original source: open the original paper. This file is not included in this text import.
Figure 4

Violin plots comparing (A) vertebral HU values and (B) patient age between the control and path-VF groups. The path-VF group exhibited significantly lower HU and higher age (*** p < 0.001).

Figure image at the original source: open the original paper. This file is not included in this text import.
Figure 5

Violin plots comparing (A) vertebral HU values and (B) age among the High-, Low-, and Zero-Dose Vit.D3 groups. The Low-Dose group showed significantly lower HU and higher age than the Zero-Dose group (** p < 0.01), while comparisons involving the High-Dose group did not reach statistical significance.

Figure image at the original source: open the original paper. This file is not included in this text import.
Table 1

Demographics of the involved patients.

Age (Years)
n Min.MeanMax.SD
Total21018.567.587.915.4
  Male8018.563.987.617.9
  Female13023.169.787.913.1
Path-VF group8453.075.387.99.0
  Male2253.074.087.010.6
  Female6252.075.887.08.5
Control group12618.562.287.616.5
  Male5818.560.087.018.7
  Female6823.064.186.014.2
Zero Vit.D3-Suplement (0 IU/Day)15718.565.187.416.1
Low Vit.D3-Suplement (<2000 IU/Day)3353.075.487.79.2
High Vit.D3-Suplement (≥2000 IU/Day)2052.473.187.911.2
Diagnosed Osteoporosis4253.076.287.98.2
  Osteoporosis with zero Vit.D3-Suplement1363.073.585.26.8
  Osteoporosis with low Vit.D3-Suplement2053.077.786.89.1
  Osteoporosis with high Vit.D3-Suplement968.579.087.97.9
Patients with Hounsfield units Value8831.969.387.712.7

Path-VF: pathological vertebral fragility, SD: Standard deviation.

Table 2

Vit.D3 Doses in At-risk and Without-risk groups.

n MeanSD p r
Path-VF group351431.41055.7<0.001 ***0.36
Control group182366.71186.7

SD: standard deviation, *** p < 0.001.

Table 3

Multiple logistic regression.

β SE β z p
(Intercept)−4.342.94−1.480.139
Gender0.640.920.690.490
Vit.D3 Dose−0.0010.0004−2.370.018*
Age0.080.042.150.031*

SE: standard error, * p < 0.05.

Publication and source details

Original title: Low-Dose Vitamin D3 Supplementation: Associations with Vertebral Fragility and Pedicle Screw Loosening

Jun Li; André Strahl; Beate Kunze; Stefan Krebs; Martin Stangenberg; Lennart Viezens; Patrick Strube; Marc Dreimann

Journal of Clinical Medicine · 2025

* Correspondence: jun.li@rkh-gesundheit.de© 2025 by the authors.2025https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).This research received no external funding.

Repository JATS snapshot; version as supplied

Source retrieved: 2026-11-11T00:48:21.793545+00:00

DOI: 10.3390/jcm14228052 · PMC12653585